Last reviewed 2026-04-22 · How we verify

Autologous BM MSC

Autologous bone marrow-derived mesenchymal stem cells (BM MSCs) are harvested from the patient's own bone marrow and administered to promote tissue repair and modulate immune responses.

At a glance

Mechanism of action

BM MSCs are multipotent cells capable of differentiating into various cell types and secreting immunomodulatory and anti-inflammatory factors. When reintroduced into the patient, they promote tissue regeneration, reduce inflammation, and support healing through paracrine effects and direct cellular replacement. This autologous approach minimizes rejection risk while leveraging the cells' inherent regenerative and immunoregulatory properties.

Approved indications

No approved indications tracked.

Common side effects

• Injection site reactions
• Fever
• Infection

Key clinical trials

• Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT (PHASE1)
• Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis (PHASE3)
• Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD (PHASE2)
• Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD (PHASE2)
• The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans (PHASE1)
• A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union (PHASE3)
• Mesenchymal Stem Cell Therapy for Liver Cirrhosis (PHASE1, PHASE2)
• Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.